Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Chen, Kui ^a   Ahmed, Sharif ^a   Adeyi, Oyedele ^b   Dick, John E ^a,c,d   Ghanekar, Anand ^a,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Campbell Family Institute for Cancer Research Ontario Cancer Institute   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD45 ANTIGEN; OLIGOCLONAL BAND; PARAPROTEIN; VIRUS RNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER MODEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; SCID MOUSE; TUMOR XENOGRAFT; VIRUS CARCINOGENESIS; VIRUS LATENCY; VIRUS REACTIVATION; XENOTRANSPLANTATION;

AGED; AGED, 80 AND OVER; ANIMALS; CELL TRANSFORMATION, VIRAL; FEMALE; GENE REARRANGEMENT; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKOCYTES; LYMPHOMA, B-CELL; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; RNA, VIRAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 84862496855     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039294     Document Type: Article

References (26)

1. Jin K, Teng L, Shen Y, He K, Xu Z, et al. (2010) Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 12: 473-480.
2. Sausville EA, Burger AM, (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66: 3351-3354, discussion 3354.
3. Clevers H, (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319.
4. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, et al. (1995) Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154: 180-191.
5. Ohbo K, Suda T, Hashiyama M, Mantani A, Ikebe M, et al. (1996) Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 87: 956-967.
6. O'Brien CA, Pollett A, Gallinger S, Dick JE, (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
7. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
8. Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, et al. (2010) Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 7: 279-282.
9. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
10. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, et al. (2008) Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14: 6456-6468.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
12. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, et al. (2009) Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 4: 1670-1680.
13. Morton CL, Houghton PJ, (2007) Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2: 247-250.
14. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, et al. (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13: 153-166.
15. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, et al. (2011) miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7: 694-707.
16. Cohen JI, (2000) Epstein-Barr virus infection. N Engl J Med 343: 481-492.
17. Vereide D, Sugden B, (2010) Insights into the evolution of lymphomas induced by Epstein-Barr virus. Adv Cancer Res 108: 1-19.
18. Birx DL, Redfield RR, Tosato G, (1986) Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med 314: 874-879.
19. Allen U, Preiksaitis J, (2009) Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 9: S87-96.
20. Mosier DE, Picchio GR, Baird SM, Kobayashi R, Kipps TJ, (1992) Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. Cancer Res 52: 5552s-5553s.
21. Young LS, Rickinson AB, (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
22. Nelson BH, (2010) CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185: 4977-4982.
23. Petrova M, Kamburov V, (2010) Epstein-Barr virus: silent companion or causative agent of chronic liver disease? World J Gastroenterol 16: 4130-4134.
24. Utsunomiya T, Okamoto M, Tsujita E, Yamamoto M, Tsutsui S, et al. (2009) Hepatocellular carcinoma infiltrated with non-Hodgkin's lymphoma: report of a case. Surg Today 39: 1010-1012.
25. Dainiak MB, Kumar A, Galaev IY, Mattiasson B, (2007) Methods in cell separations. Adv Biochem Eng Biotechnol 106: 1-18.
26. Visvader JE, (2011) Cells of origin in cancer. Nature 469: 314-322.